» Articles » PMID: 20234332

Toward Earlier Detection of Choroidal Neovascularization Secondary to Age-related Macular Degeneration: Multicenter Evaluation of a Preferential Hyperacuity Perimeter Designed As a Home Device

Abstract

Purpose: The primary purpose of this study was to evaluate the ability of a home device preferential hyperacuity perimeter to discriminate between patients with choroidal neovascularization (CNV) and intermediate age-related macular degeneration (AMD), and the secondary purpose was to investigate the dependence of sensitivity on lesion characteristics.

Methods: All participants were tested with the home device in an unsupervised mode. The first part of this work was retrospective using tests performed by patients with intermediate AMD and newly diagnosed CNV. In the second part, the classifier was prospectively challenged with tests performed by patients with intermediate AMD and newly diagnosed CNV. The dependence of sensitivity on lesion characteristics was estimated with tests performed by patients with CNV of both parts.

Results: In 66 eyes with CNV and 65 eyes with intermediate AMD, both sensitivity and specificity were 0.85. In the retrospective part (34 CNV and 43 intermediate AMD), sensitivity and specificity were 0.85 +/- 0.12 (95% confidence interval) and 0.84 +/- 0.11 (95% confidence interval), respectively. In the prospective part (32 CNV and 22 intermediate AMD), sensitivity and specificity were 0.84 +/- 0.13 (95% confidence interval) and 0.86 +/- 0.14 (95% confidence interval), respectively. Chi-square analysis showed no dependence of sensitivity on type (P = 0.44), location (P = 0.243), or size (P = 0.73) of the CNV lesions.

Conclusion: A home device preferential hyperacuity perimeter has good sensitivity and specificity in discriminating between patients with newly diagnosed CNV and intermediate AMD. Sensitivity is not dependent on lesion characteristics.

Citing Articles

[Digital remote monitoring of chronic retinal conditions-A clinical future tool? : Remote monitoring of chronic retinal conditions].

Terheyden J, Mauschitz M, Wintergerst M, Chang P, Herrmann P, Liegl R Ophthalmologie. 2024; 121(10):826-834.

PMID: 39276227 DOI: 10.1007/s00347-024-02109-2.


Additional measures of macular function beyond visual acuity.

Rios H, Lovestam-Adrian M, Plainis S, Tsilimbaris M, Joussen A, Keegan D Graefes Arch Clin Exp Ophthalmol. 2023; 262(6):1723-1736.

PMID: 37938378 PMC: 11106142. DOI: 10.1007/s00417-023-06272-1.


Patient Use of Dietary Supplements, Home Monitoring, or Genetic Testing for Nonneovascular Age-Related Macular Degeneration.

Tsou B, Liu T, Kong J, Bressler S, Fernando Arevalo J, Brady C J Vitreoretin Dis. 2023; 5(5):389-395.

PMID: 37008702 PMC: 9976132. DOI: 10.1177/2474126421989228.


A Systematic Review of Current Teleophthalmology Services in New Zealand Compared to the Four Comparable Countries of the United Kingdom, Australia, United States of America (USA) and Canada.

Walsh L, Chiong Hong S, Chalakkal R, Ogbuehi K Clin Ophthalmol. 2021; 15:4015-4027.

PMID: 34675470 PMC: 8500493. DOI: 10.2147/OPTH.S294428.


Accuracy of a Self-monitoring Test for Identification and Monitoring of Age-related Macular Degeneration: A Diagnostic Case-control Study.

Schmid M, Faes L, Bachmann L, Thiel M Open Ophthalmol J. 2018; 12:19-28.

PMID: 29619125 PMC: 5861526. DOI: 10.2174/1874364101812010019.